	销售和管理费用		日
AbbVie	USD 3.58B	316M	2026-03
Amgen	USD 1.58B	354M	2026-03
Anika Therapeutics	USD 10.01M	14K	2025-12
Arrowhead Research	USD 46.02M	8.84M	2025-12
AstraZeneca	USD 5.06B	455M	2026-03
BioCryst Pharmaceuticals	USD 95.78M	12.77M	2025-12
Biogen	USD 554.3M	128.2M	2026-03
Bristol-Myers Squibb	USD 1.62B	564M	2026-03
Enanta Pharmaceuticals	USD -1.05	0.31	2024-12
Gilead Sciences	USD 1.78B	425M	2025-12
GlaxoSmithKline	GBP 2.12B	558M	2026-03
Halozyme Therapeutics	USD 64.64M	27.11M	2025-12
Heron Therapeutics	USD 23.74M	605K	2025-12
Immunic	USD 3.45M	451K	2025-12
Incyte	USD 328.1M	62.31M	2026-03
Insmed	USD 212.48M	26.11M	2025-12
Ionis Pharmaceuticals	USD 151M	21M	2026-03
J&J	USD 6.03B	719M	2026-03
Karyopharm Therapeutics	USD 9.56M	17.63M	2025-12
Ligand Pharmaceuticals	USD 28.45M	8.27M	2025-09
Merck	USD 2.67B	180M	2026-03
Neurocrine Biosciences	USD 301.8M	10.2M	2025-12
Novartis	USD 3.14B	296M	2026-03
Novavax	USD 25.53M	1.34M	2025-12
Pfizer	USD 4.08B	894M	2025-12
PTC Therapeutics	USD 87.2M	3.15M	2025-12
Roche Holding	CHF 7.28B	3.99B	2025-12
Sarepta Therapeutics	USD 105.38M	28.27M	2025-12
Vertex Pharmaceuticals	USD 493.7M	6.7M	2026-03